NRXP — NRX Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1719406 ·
Last close
$4.19
Market Cap
$179.33M
52W High
$5.05
52W Low
$2.18
ADV30
1,256,660
Next earnings
2026-08-14
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,068,000 | 437,000 | -4,748,000 | -1,430,000 | 11,903,000 | 6,713,000 | 25,719,000 |
| Dec 2025 | 983,000 | 575,000 | -4,624,000 | 360,000 | 12,956,000 | 7,797,000 | 28,893,000 |
| Sep 2025 | 242,000 | 145,000 | -4,024,000 | -5,890,000 | 14,996,000 | 7,184,000 | 40,751,000 |
| Jun 2025 | 0 | — | -3,730,000 | -17,581,000 | 4,838,000 | 2,910,000 | 40,453,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,927,000
Investing CF
$-462,000
Financing CF
$19,115,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.63
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-308,325,000
Inventory
—
Receivables
$181,000
ST Investments
—
EBIT TTM
$-23,637,000
Pretax Income TTM
$-24,541,000
Interest Exp TTM
$904,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,293,000
EBITDA
$-17,057,000
Free Cash Flow
$-8,542,125
Enterprise Value
$142,986,960
Total Cash
$6,713,000
Total Debt
$934,000
Shares Out
42,800,420
Trailing EPS
$-1.04
Book Value
$-0.41
ROE
—
ROA
-110.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,225,000 | -16,224,000 | -28,622,000 | 12,956,000 | 28,893,000 | — | -14,112,000 |
| Dec 2024 | 0 | -18,502,000 | -25,126,000 | 3,651,000 | 26,874,000 | — | -10,637,000 |
| Dec 2023 | 0 | -27,587,000 | -30,150,000 | 7,315,000 | 19,048,000 | — | -21,657,000 |
| Dec 2022 | 0 | -44,335,000 | -39,754,000 | 25,816,000 | 18,407,000 | — | -39,755,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.50
Max Pain — expiry 2026-09-18
max pain strike: $2.50 · spot: $4.19 · call oi: 8,050 · put oi: 317
Expected Move to 2026-09-18:
±$2.20
(52.51%) —
implied range
$1.99 –
$6.39
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $179.35M | $9.68 | — |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $178.17M | $4.75 | — |
| CNTN | Canton Strategic Holdings, Inc. | $183.55M | $2.38 | — |
| EQ | Equillium, Inc. | $183.99M | $2.91 | — |
| OKUR | OnKure Therapeutics, Inc. | $172.89M | $4.28 | — |
News headlines (Yahoo Finance, 1h cache)
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
2026-06-25 20:01 · Yahoo
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
2026-06-25 11:00 · Yahoo
Sector Update: Healthcare Stocks Advance Late Afternoon
2026-06-24 19:32 · Yahoo
Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition
2026-06-24 17:18 · Yahoo
ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics
2026-06-23 15:05 · Yahoo
NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
2026-06-22 11:00 · Yahoo
NRX Pharmaceuticals Inc (NRXP) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
2026-06-17 22:19 · Yahoo
NRx Pharmaceuticals (NRXP) Closes Underwritten Public Offering of Common Stock At $3.50 Per Share
2026-06-10 18:22 · Yahoo
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
2026-06-05 12:50 · Yahoo
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option
2026-06-04 21:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.